Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
High dose chemotherapy and radiation used as preparative regimens in patients undergoing an
allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by
damaging the intestinal epithelium and altering the intestinal microbiome. The investigators
hypothesize that 2'-fucosyllactose (2FL) supplementation will be safe and tolerable and
result in an increase in the relative abundance of intestinal Bifidobacteria. The
investigators also hypothesize that 2FL supplementation will lead to reduction of Firmicutes
and/or Proteobacteria, and improved intestinal homeostasis at day+30 as measured by lower
pro-inflammatory cytokines, reduced levels of T-cell activation, lower markers of intestinal
injury (fecal human DNA and plasma reg-3-alpha), increased fecal butyrate levels and
ultimately lower incidence of acute GVHD and BSI at day+100.